Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $5M | $-57M | $-58M | $-47M | 133.9% | 8.3% | 27.4% |
| 2024 | $4M | $-44M | $-46M | $-45M | 92.9% | 79.0% | -13.6% |
| 2023 | $2M | $-50M | $-53M | $-33M | 251.6% | 544.0% | -6.2% |
| 2022 | $0M | $-54M | $-56M | $-31M | -243.7% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 4.71 |
| Operating Revenue | 4.71 |
| Cost Of Revenue | 6.67 |
| Gross Profit | -1.96 |
| Operating Expense | 47.68 |
| Research And Development | 5.68 |
| Selling General And Administration | 41.58 |
| Total Expenses | 54.35 |
| Operating Income | -49.64 |
| Total Operating Income As Reported | -49.64 |
| EBITDA | -57.12 |
| Normalized EBITDA | -57.12 |
| EBIT | -57.99 |
| Interest Income | 0.39 |
| Interest Expense | 0.02 |
| Net Interest Income | 0.36 |
| Other Non Operating Income Expenses | -8.73 |
| Other Income Expense | -8.73 |
| Interest Income Non Operating | 0.39 |
| Interest Expense Non Operating | 0.02 |
| Net Non Operating Interest Income Expense | 0.36 |
| Pretax Income | -58.01 |
| Tax Provision | 0 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -58.01 |
| Net Income From Continuing And Discontinued Operation | -58.01 |
| Net Income From Continuing Operation Net Minority Interest | -58.01 |
| Net Income | -58.01 |
| Net Income Common Stockholders | -70.57 |
| Net Income Including Noncontrolling Interests | -58.01 |
| Normalized Income | -58.01 |
| Diluted NI Availto Com Stockholders | -70.57 |
| Basic Average Shares | 164.11 |
| Diluted Average Shares | 164.11 |
| Reconciled Depreciation | 0.87 |
| Reconciled Cost Of Revenue | 6.22 |
| Total Unusual Items | 0 |
| Total Unusual Items Excluding Goodwill | 0 |
| Preferred Stock Dividends | 12.56 |
| Special Income Charges | 0 |
| Other Special Charges | - |
| Depreciation Amortization Depletion Income Statement | 0.42 |
| Depreciation And Amortization In Income Statement | 0.42 |
| General And Administrative Expense | 23.87 |
| Other Gand A | 23.87 |
| Selling And Marketing Expense | 17.71 |
| Amortization | 0.42 |
| Amortization Of Intangibles Income Statement | 0.42 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Lucid Diagnostics Inc.this co. | LUCD | $195M | - | 17.79 | -645.1% | - |
| TriSalus Life Sciences, Inc. | TLSI | $203M | -5.17 | -5.99 | 115.8% | -6.56 |
| Embecta Corp. | EMBC | $202M | 2.12 | -0.31 | -14.6% | 4.95 |
| Alector, Inc. | ALEC | $201M | - | 6.56 | -466.3% | - |
| Nkarta, Inc. | NKTX | $198M | - |
| - |
| - |
| - |
| - |
| - |
| - |
| 0.63 |
| -33.3% |
| - |
| Anika Therapeutics, Inc. | ANIK | $197M | -18.09 | 1.37 | -7.6% | -31.11 |
| Cartesian Therapeutics, Inc. | RNAC | $192M | -1.48 | -1.52 | 103.2% | -0.96 |
| KORU Medical Systems, Inc. | KRMD | $190M | -72.09 | 11.15 | -15.5% | -85.47 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $189M | -1.53 | 0.77 | -50.6% | 0.14 |
| Peer Median | - | -3.35 | 0.70 | -15.1% | -3.76 | |